Clinical Laserthermia Systems AB receives approx. SEK 12.8 million through warrant exercise
Lund, Sweden – On 28 February 2023, the exercise period for warrants of series TO 5 B, which were issued in connection with Clinical Laserthermia Systems AB’s ("CLS" or the "Company") rights issue of units that was announced on 10 August 2022, ended. In total, 25,315,836 warrants of series TO 5 B were exercised, corresponding to a subscription ratio of approximately 91.3 percent. Thus, the underwriting commitment relating to TO 5 B, which the Company agreed on during the exercise period, is activated. The formal decision on a directed share issue of 2,406,784 B-shares to the underwriters is